12 mar 2019
CPhI South East Asia 2019
Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Exhibitor at CPhI South East Asia 2019 stand A16

About us

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, having over 17,000 employees globally, is the largest manufacturer of antineoplastic drugs, surgical drugs and contrast media in China. Its operating income was over USD 2.4 billion in 2018. All APIs and finish dosage forms have passed national GMP authentication. APIs are approved by US-FDA, EDQM, PMDA and TGA. FDFs are approved by US-FDA, EU and PMDA.

Specs about this supplier

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: APIs |Finished Dosage Forms |Injectables More

Products featured at CPhI South East Asia 2019

Categories affiliated with Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Event information

CPhI South East Asia 2019

12-14 March 2019 Bangkok, Thailand Visit us at stand A16